PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors (Q34769343)

4 August 2017

title

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors (English)

1 reference

4 August 2017

Razelle Kurzrock

1 reference

4 August 2017

Ignacio Garrido-Laguna

object named as

Ignacio Garrido-Laguna

1 reference

Apostolia Maria Tsimberidou

4 August 2017

object named as

Apostolia M Tsimberidou

1 reference

4 August 2017

Aung Naing

1 reference

4 August 2017

Filip Janku

1 reference

4 August 2017

Gerald S Falchook

1 reference

4 August 2017

Xuemei Wang

1 reference

4 August 2017

Rajyalakshmi Luthra

1 reference

4 August 2017

David S Hong

1 reference

4 August 2017

John W Moroney

1 reference

4 August 2017

Sarina A Piha-Paul

1 reference

4 August 2017

Jennifer J Wheler

1 reference

4 August 2017

Stacy L Moulder

1 reference

4 August 2017

Siqing Fu

1 reference

4 August 2017

publication date

7 January 2011

1 reference

Molecular Cancer Therapeutics

4 August 2017

published in

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

558-565

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

PIK3CA alterations in Middle Eastern ovarian cancers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

PIK3CA mutations in head and neck squamous cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Erlotinib in previously treated non-small-cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

High frequency of mutations of the PIK3CA gene in human cancers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Frequent mutation of the PIK3CA gene in ovarian and breast cancers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072168

Cancer: the road to Amiens

26 October 2018

1 reference

12 December 2020

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

12 December 2020

Risks and benefits of phase 1 oncology trials, revisited

1 reference

12 December 2020

Uncommon tumors and exceptional therapies: paradox or paradigm?

1 reference

12 December 2020

10.1158/1535-7163.MCT-10-0994

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference